Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 7Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Leukemia, Myeloid, Acute 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Thrombocytosis 1Prostatic Neoplasms 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, B-Cell 1Leukemia 1Hodgkin Disease 1Hematologic Neoplasms 1Disease 1Breast Neoplasms 1

Interventions

Cyclophosphamide 37Rituximab 31fludarabine phosphate 26Filgrastim 20ibrutinib 19Bortezomib 19fludarabine 17Peripheral Blood Stem Cell Transplantation 15Lenalidomide 15Bendamustine Hydrochloride 14Etoposide 12Cytarabine 9aldesleukin 7Vorinostat 7Tacrolimus 7Radiotherapy 7Prednisone 7Paclitaxel 7Melphalan 7Cyclosporine 7Biopsy 7venetoclax 6tanespimycin 6sargramostim 6Magnetic Resonance Spectroscopy 6Flow Cytometry 6Carmustine 6Vincristine 5Specimen Handling 5Polymerase Chain Reaction 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, Mantle-Cell × idelalisib × Clear all
NCT03151057 2024-03-12

Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Terminated
16 enrolled 11 charts
LymphoidOther hematologic neoplasm

Disease, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT01088048 2021-03-18

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Gilead Sciences

Phase 1 Completed
241 enrolled 31 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT02603445 2020-02-24

Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL

Novartis

Phase 1 Completed
20 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Mantle-Cell

NCT01838434 2018-01-30

Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Alliance for Clinical Trials in Oncology

Phase 1 Completed
106 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡